Efficacy and safety of Lenalinomide combined to Rituximab in patients with relapsed/refractory diffuse large B cell lymphoma
Leukemia & lymphoma | 11 Feb 2014
V Ivanov, D Coso, B Chetaille, B Esterni, D Olive, T Aurran-Schleinitz, JM Schiano, AM Stoppa, F Broussais-Guillaumot, D Blaise and R Bouabdallah
ABSTRACT Initial clinical trials demonstrated that lenalidomide monotherapy has a significant activity against some subtypes of lymphoma, but in diffuse large B-cell lymphoma (DLBCL) its activity is limited. Combination of lenalidomide with rituximab may be a promising therapeutic strategy. We retrospectively analyzed clinical outcomes in 17 relapsed/refractory (R/R) DLBCL patients, treated with lenalidomide, 25 mg/d for 21/28 days and rituximab, 375 mg/m(2) on day 7 of every lenalidomide cycle, for a maximum of 12 months. The ORR was 41.2% with 35.3% CR, while median response duration was 26.5 months at a median follow-up of 24.9 months. Two CR patients relapsed after 4 and 27 months of CR, and other 4 are actually in CR at +13,+23+24 and +29 months. The estimated 24-months OS was 45% and PFS was 38%. Adverse events were manageable and mostly included thrombocytopenia and neutropenia. Lenalidomide-rituximab is active in R/R DLBCL with important percentage of continuous CR.
* Data courtesy of Altmetric.com